Earnings per share for the last twelve months: MacroGenics Inc. (MGNX)

MGNX (MacroGenics Inc) - company brandmark

MacroGenics, Inc. (MGNX) relies on the expertise of seasoned management with transparent clinical trial reporting. The expert team effectively combines the development of proprietary antibodies with strategic licensing. The 12-month net income per share trend on the GURU.Markets chart clearly demonstrates profitability, where the value -0.82 determines the metric's magnitude. Growth prospects are supported by the implementation of AI software and the robotization of bio-screening.

MGNX (MacroGenics Inc.) Net earnings per share for the last 12 months history from 07/04/2022 to 11/14/2026

Analytical breakdowns for MacroGenics Inc (MGNX)

- stock price and consensus target price:
Stock Price MacroGenics, Inc.|MGNX - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Value MacroGenics, Inc.|MGNX - Business Value
- shareholders' equity book value data:
Book Value per Share MacroGenics|MGNX - Company Net Assets|Market Capitalization to Book Value Ratio macrogenics.com|MGNX - Company Assets
- debt burden and liquidity indicators:
Debt to Equity MacroGenics, Inc.|MGNX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity MacroGenics Corp|MGNX - Company Total Debt|Debts to Book Capitalization MacroGenics, Inc.|MGNX - Company Long-Term Debts|Company Short-Term Debts MacroGenics|Quick Liquidity macrogenics.com
- net income and valuation multiples indicators:
MGNX - Final Profit|Expected Profit MacroGenics, Inc.|MGNX - Market Cap to Earnings|Forward P/E Multiple MacroGenics|MGNX - Price to Net Income Growth Ratio|EV/EBITDA Multiple MacroGenics, Inc.|MGNX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months MacroGenics|MGNX - Earnings per share for the last 12 months|Quarterly EPS earnings growth macrogenics.com|MGNX - Expected net earnings per share growth this year|Earnings growth forecast for next year MacroGenics, Inc.
- revenue and sales details:
MGNX - Company Sales|Company Projected Revenue MacroGenics, Inc.|MGNX - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple MacroGenics, Inc.
Initial company analysis:MacroGenics, Inc. (MGNX)
Mass-produced product of MacroGenics Corp

For the MacroGenics, Inc. (MGNX) biotech model, the 12-month net income per share trend serves as an indicator of actual development monetization. This metric is calculated by dividing the total annual net income by the number of shares outstanding. It measures the actual profit share attributable to a single share, excluding the impact of dilution. Strict R&D expenditure control by management makes this trend a transparent tool for capital valuation. The upward trajectory of the line confirms the asset's operational efficiency and investment attractiveness.

Competitors of MacroGenics, Inc. (MGNX)

Olema Pharmaceuticals - Net earnings per share (EPS TTM)|PBYI - Net earnings per share (EPS TTM)|Greenwich LifeSciences, Inc. (GLSI) - Earnings per share for the last twelve months|Earnings per share for the last 12 months ZNTL|PSTV (Plus Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Processa Pharma (PCSA)|Net earnings per share (EPS TTM) EGRX